TherapeuticsMD, Inc. (TXMD)
TXMD Stock Price Chart
Explore TherapeuticsMD, Inc. interactive price chart. Choose custom timeframes to analyze TXMD price movements and trends.
TXMD Company Profile
Discover essential business fundamentals and corporate details for TherapeuticsMD, Inc. (TXMD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
9 May 2007
Employees
1.00
Website
https://www.therapeuticsmd.comCEO
Marlan D. Walker
Description
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TXMD Financial Timeline
Browse a chronological timeline of TherapeuticsMD, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 10 Nov 2025
Earnings released on 12 Aug 2025
EPS came in at $0.05 , while revenue for the quarter reached $952.00K .
Earnings released on 13 May 2025
EPS came in at -$0.06 , while revenue for the quarter reached $393.00K .
Earnings released on 27 Mar 2025
EPS came in at $0.02 falling short of the estimated $0.04 by -45.38%, while revenue for the quarter reached $667.00K , missing expectations by -71.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.05 falling short of the estimated $0.04 by -225.00%, while revenue for the quarter reached $547.00K , missing expectations by -76.22%.
Earnings released on 12 Aug 2024
EPS came in at -$0.09 falling short of the estimated $0.03 by -400.00%, while revenue for the quarter reached $234.00K , missing expectations by -53.20%.
Earnings released on 10 May 2024
EPS came in at -$0.07 falling short of the estimated $0.03 by -333.33%, while revenue for the quarter reached $313.00K , missing expectations by -37.40%.
Earnings released on 29 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.13 by +38.46%, while revenue for the quarter reached $502.00K , beating expectations by +0.40%.
Earnings released on 14 Nov 2023
EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%, while revenue for the quarter reached -$53.00K , missing expectations by -110.60%.
Earnings released on 14 Aug 2023
EPS came in at -$0.24 falling short of the estimated -$0.07 by -242.86%, while revenue for the quarter reached $437.00K , missing expectations by -12.60%.
Earnings released on 15 May 2023
EPS came in at -$0.24 falling short of the estimated $0.06 by -500.00%, while revenue for the quarter reached $416.00K , missing expectations by -75.53%.
Earnings released on 27 Mar 2023
EPS came in at -$3.55 falling short of the estimated -$1.11 by -219.55%, while revenue for the quarter reached $1.15M , missing expectations by -95.16%.
Earnings released on 14 Nov 2022
EPS came in at -$3.13 falling short of the estimated -$2.04 by -53.43%, while revenue for the quarter reached $20.92M , missing expectations by -21.95%.
Earnings released on 15 Aug 2022
EPS came in at -$2.15 surpassing the estimated -$3.04 by +29.28%, while revenue for the quarter reached $28.56M , beating expectations by +23.11%.
Earnings released on 16 May 2022
EPS came in at -$4.72 falling short of the estimated -$3.50 by -34.86%, while revenue for the quarter reached $19.33M , beating expectations by +7.67%.
Stock split effective on 9 May 2022
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Mar 2022
EPS came in at -$4.50 falling short of the estimated -$3.00 by -50.00%, while revenue for the quarter reached $18.68M , missing expectations by -36.45%.
Earnings released on 11 Nov 2021
EPS came in at -$5.50 falling short of the estimated -$5.00 by -10.00%, while revenue for the quarter reached $25.41M , missing expectations by -1.80%.
Earnings released on 4 Aug 2021
EPS came in at -$5.50 matching the estimated -$5.50, while revenue for the quarter reached $23.00M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$5.50 falling short of the estimated -$5.00 by -10.00%, while revenue for the quarter reached $19.87M , missing expectations by -7.69%.
Earnings released on 2 Mar 2021
EPS came in at -$7.50 falling short of the estimated -$5.00 by -50.00%, while revenue for the quarter reached $22.58M .
Earnings released on 9 Nov 2020
EPS came in at -$5.00 surpassing the estimated -$7.00 by +28.57%, while revenue for the quarter reached $19.34M , missing expectations by -12.50%.
TXMD Stock Performance
Access detailed TXMD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.